Cancer is Striking Patients At a Younger Age: New Screening Recommendations to Know
Colon Cancer: Rising Rates Among Younger Patients
Breast Cancer Screening – Updated Recommendations
The U.S. Preventive Services Task Force in May came out with the recommendation that women should be screened for breast cancer starting at age 40, not 50, as was the previous screening recommendation. While the task force states these screenings can be every other year, the American College of Radiology (ACR) is calling for annual breast screening for women 40 and up AND even earlier screening for high-risk women.
The ACR has additional recommendations for Breast MRI:
- Women with genetics-based increased risk (including BRCA1 carriers), those with a calculated lifetime risk of 20% or more, and those exposed to chest radiation at a young age are recommended to have MRI surveillance starting at ages 25 to 30. These women should start annual mammography at ages 25 to 40, depending on type of risk.
- Women diagnosed with breast cancer prior to age 50 or with a personal history of breast cancer and dense breasts should have annual supplemental breast MRI.
PET/CT Breast Screening
MRI Breast Screening
PSMA PET/CT – IMPORTANT UPDATE!
Charter Radiology is excited to roll out its use of Illuccix®.
- With suspected metastasis who are candidates for initial definitive therapy
- With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- For a selection of patients with metastatic prostate cancer for whom Lu177 vipivotide tetraxetan PSMA-directed therapy is indicated.
- Ga-68-PSMA-11 PET/CT is well tolerated.
- The safety profile of Illuccix® has been established based on three prospective studies of another formulation of gallium Ga 68 gozetotide in patients with prostate cancer.
- No serious adverse reactions were attributed to 68Ga-PSMA-11 Injection.
Charter Radiology can image patients with Medicare, BCBS, and AETNA.